BioCentury | Mar 16, 2021
Product Development

The clinical pipeline for Alzheimer’s disease: Data Byte

Although amyloid-lowering agents still represent the lion’s share of late-stage candidates for Alzheimer’s disease, they account for less than 20% of compounds across all clinical stages. Tau inhibition, modulation of neurotransmitter signaling, and quelling of...
BioCentury | Feb 24, 2021

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

BGI Genomics Co. Ltd. (SZSE:300676) raised RMB2 billion ($309 million) through the sale of 13.8 million shares at RMB145 in a private placement. Huatai Securities Co. Ltd. purchased 8.3 million shares; also buying shares were China...
BioCentury | May 22, 2020
Emerging Company Profile

With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers

Day One is using its $60 million series A round to acquire and develop cancer therapies that target biology shared by pediatric and adult cancers, capitalizing on growing understanding and clinical trial infrastructure to make...
BioCentury | Apr 9, 2020

As Tango moves toward clinic with $60M series B, another partnership could precede IPO

Although synthetic lethality company Tango’s $60 million series B round includes crossover investors who might normally signal that an IPO is in the offing, President and CEO Barbara Weber thinks the wealth of targets that...
BioCentury | Nov 7, 2019
Product Development

AZ replants R&D roots in China, goes all-in on innovation

In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation. As...
BioCentury | Oct 3, 2019
Targets & Mechanisms

Blocking the MAPK pathway for Trk inhibitor resistant cancers

Targeting the MAPK pathway could be a key to overcoming a new mechanism of tissue-agnostic therapy resistance identified by a Memorial Sloan Kettering Cancer Center team. FDA has approved two inhibitors of TrkA, TrkB and...
BioCentury | Aug 15, 2019
Distillery Techniques

A new KRAS inhibitor that targets a previously undruggable site

TECHNIQUES CATEGORY: Chemistry TECHNOLOGY: Tool compounds Boehringher Ingelheim GmbH and Vanderbilt University developed a KRAS inhibitor tool compound targeting a site previously considered undruggable that could enable the development of inhibitors for cancers without the...
BioCentury | Aug 14, 2019
Distillery Therapeutics

RASGRF2-MEK inhibition for cocaine addiction

DISEASE CATEGORY: Neurology INDICATION: Addiction Blocking phosphorylation of MAPK1 and MAPK3 in the nucleus accumbens region of the brain by inhibiting RASGRF2-MEK signaling could treat cocaine addiction. In a mouse model of the addiction, the...
BioCentury | Jun 18, 2019
Company News

BeiGene, SpringWorks form MapKure to develop BRAF inhibitor

Nine months after partnering to test a BRAF-MEK combination therapy, BeiGene and Pfizer spinout SpringWorks are collaborating again, this time forming a joint venture to develop a BeiGene BRAF inhibitor that could lead to combination...
BioCentury | Jun 3, 2019
Clinical News

June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more

Celgene highlights iberdomide data for MM at ASCO Celgene Corp. (NASDAQ:CELG) presented data at ASCO Sunday showing that iberdomide (CC-220) plus dexamethasone led to an overall response rate (ORR) of 32%, including 17 partial responses...
Items per page:
1 - 10 of 171